Decision guide for radioactive iodine treatment in intermediate-risk thyroid cancer
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer: The Radiance Trial
NA · Georgetown University · NCT06980103
This study tests whether a web-based decision aid helps adults newly diagnosed with intermediate-risk differentiated thyroid cancer decide about radioactive iodine treatment, compared with standard American Cancer Society information.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 408 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Georgetown University (other) |
| Locations | 3 sites (Washington D.C., District of Columbia and 2 other locations) |
| Trial ID | NCT06980103 on ClinicalTrials.gov |
What this trial studies
This randomized study enrolls adults diagnosed within the past six months with intermediate-risk differentiated thyroid cancer who are facing the decision about radioactive iodine (RAI) treatment. Participants are randomly assigned to view a tailored web-based decision aid (RAI Decisions) with videos, expandable details, values clarification exercises, and question-preparation tools, or to receive standard educational material from the American Cancer Society website. The study measures participants' understanding of RAI risks and benefits, whether choices align with individual values, and overall decision quality. Results will compare informed, values‑concordant decision-making between the decision aid and usual care groups.
Who should consider this trial
Good fit: Adults (18+) diagnosed within the past six months with intermediate‑risk differentiated thyroid cancer who are deciding about RAI, able to consent and use web-based materials, and without prior RAI or contraindications are ideal candidates.
Not a fit: Patients with low‑risk or high‑risk disease, prior RAI treatment, clinical contraindications to RAI (for example pregnancy or lactation), or inability to use web-based tools are unlikely to benefit.
Why it matters
Potential benefit: If successful, the decision aid could help patients better understand the risks and benefits of RAI and make treatment choices that match their priorities, potentially avoiding unnecessary treatment.
How similar studies have performed: Decision aids in other cancer treatment decisions have improved patient knowledge and decision quality, but RAI-specific decision aids for intermediate‑risk thyroid cancer are relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 and older * Patients diagnosed with intermediate risk DTC \< 6 months ago and who are making a decision about RAI treatment * Ability to understand the information conveyed in the informed consent form, pose questions and process answers (e.g., no cognitive impairment per direct consultation with the patient's physician), and, finally, provided informed consent to participate. * Participants willingness to be contacted and remain available to complete study activities throughout the duration of the study. Exclusion Criteria: * Diagnosis of low risk or high risk DTC * Prior history of RAI * Clinical contraindications that prevent consideration of RAI (e.g., pregnancy, lactation, neutropenia if considering high dose of RAI)
Where this trial is running
Washington D.C., District of Columbia and 2 other locations
- Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia, United States (RECRUITING)
- MedStar Washington Hospital Center — Washington D.C., District of Columbia, United States (RECRUITING)
- Inova Health System — Falls Church, Virginia, United States (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Thyroid Cancer, Decision Aid, Radioactive Iodine Treatment, Intermediate Risk, Differentiated Thyroid Cancer, Intermediate risk DTC